Discover the transformation of antibody-drug conjugates (ADCs) from experimental to essential in cancer therapy with new advancements.

Highlights strategic progress achieved under Abizer Gaslightwala’s leadership, including advancement of AKTX-101 and ...

Add Yahoo as a preferred source to see more of our stories on Google. Innovation in linkers Antibody-drug conjugate (ADC) developers say innovations to linkers, the proteins bridging antibodies to ...

Grace Liu (left) is a Technical Account Manager at Sino Biological US Inc. (PA, USA). Grace joined Sino Biological in 2022, supporting CRO services and project management in the western and central US ...

SEATTLE--(BUSINESS WIRE)--ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for cancer, today announced multiple data presentations at the ...

Antibody–drug conjugates (ADCs) are a class of molecules that provide a means of targeted delivery of cytotoxic agents to tumor cells. ADCs are composed of three components: a monoclonal antibody ...

Antibody-drug conjugates (ADCs) continue to reshape the oncology landscape by combining the target specificity of monoclonal antibodies (mAbs) with the potent cytotoxicity of small-molecule drugs.

Aadi Enters into Exclusive License for Three-Asset ADC Portfolio Developed through a Collaboration between WuXi Biologics and HANGZHOU DAC Each of the three ADC assets utilizes HANGZHOU DAC's CPT113 ...

Antibody-drug conjugate (ADC) is a promising class of cancer treatments with accelerating U.S. Food and Drug Administration (FDA) approval and rapidly growing market size as discussed in previous ...